Compare FEIM & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FEIM | PMVP |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 494.3M | 66.0M |
| IPO Year | N/A | 2020 |
| Metric | FEIM | PMVP |
|---|---|---|
| Price | $53.39 | $1.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | ★ $42.50 | $5.00 |
| AVG Volume (30 Days) | ★ 358.3K | 251.1K |
| Earning Date | 12-11-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 163.76 | N/A |
| EPS | ★ 2.17 | N/A |
| Revenue | ★ $69,852,000.00 | N/A |
| Revenue This Year | $5.52 | N/A |
| Revenue Next Year | $17.07 | N/A |
| P/E Ratio | $23.34 | ★ N/A |
| Revenue Growth | ★ 16.06 | N/A |
| 52 Week Low | $13.69 | $0.81 |
| 52 Week High | $59.38 | $1.84 |
| Indicator | FEIM | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 67.50 | 44.43 |
| Support Level | $47.54 | $1.21 |
| Resistance Level | $58.27 | $1.27 |
| Average True Range (ATR) | 4.35 | 0.06 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 67.54 | 55.56 |
Frequency Electronics Inc is engaged in the design, development, and manufacture of high-precision timing, and frequency control products for space, air, sea, and terrestrial applications. The company has FEI-NY and FEI-Zyfer reportable segments. It derives the majority of its revenues from the FEI-NY segment. FEI-NY segment operations consist principally of precision time and frequency control products used in three principal markets namely communication satellites (both commercial and U.S. Government-funded); terrestrial cellular telephone or other ground-based telecommunication stations; and other components and systems for the U.S. military.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.